Who are DA-3801 Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ngenla, Ngenla, Skytrofa, Sogroya, Trovert, Trovert.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/da-3801-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

DA-3801 Injection — Competitive Intelligence Brief

DA-3801 Injection (DA-3801 Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth hormone analog. Area: Endocrinology.

phase 3 Growth hormone analog Growth hormone receptor Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

DA-3801 Injection (DA-3801 Injection) — Dong-A ST Co., Ltd.. DA-3801 is a recombinant human growth hormone analog designed to promote growth and metabolic effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DA-3801 Injection TARGET	DA-3801 Injection	Dong-A ST Co., Ltd.	phase 3	Growth hormone analog	Growth hormone receptor
Ngenla	somatrogon	Pfizer Ireland Pharmaceuticals	marketed		Growth hormone receptor	2023-01-01
Ngenla	Somatrogon-Ghla	Pfizer Ireland Pharmaceuticals	marketed		Growth hormone receptor	2023-01-01
Skytrofa	LONAPEGSOMATROPIN	Ascendis Pharma Encocrinology Div A/S	marketed	Recombinant Human Growth Hormone [EPC]	Growth hormone receptor	2021-01-01
Sogroya	SOMAPACITAN	Novo Nordisk	marketed		Growth hormone receptor	2020-01-01
Trovert	PEGVISOMANT	Pfizer	marketed	Growth Hormone Receptor Antagonist	Growth hormone receptor	2003-01-01
Trovert	somavert	Pfizer	marketed	Growth Hormone Receptor Antagonist	Growth hormone receptor	2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth hormone analog class)

Changchun GeneScience Pharmaceutical Co., Ltd. · 2 drugs in this class
Ascendis Pharma A/S · 1 drug in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Theratechnologies · 1 drug in this class
Xiamen Amoytop Biotech Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DA-3801 Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/da-3801-injection. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab